logo-loader
RNS
viewe-Therapeutics plc

Holding(s) in Company

/**/ sup{font-size:80%}link{ color: #000000 }visited{ color: fuchsia } .j{size:612.0pt 792.0pt;margin:72.0pt 3.0cm 72.0pt 53.85pt;}div.j{}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;}span.el{font-size:10.0pt;font-family:"Arial","sans-serif"}table.en{margin-left:1.4pt;border-collapse:collapse;border:none}tr.eg{height:13.1pt}td.ei{width:202.95pt;border:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:13.1pt}p.eo{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;font-weight: bold}span.ek{font-size:10.0pt;font-family: "Arial","sans-serif";color:windowtext}td.eh{width:248.85pt;border:none;padding: 4.0pt 4.0pt 4.0pt 4.0pt;height:13.1pt} tr.ed{height:11.65pt}td.ee{width:459.8pt;border:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:11.65pt}span.ef{font-size:10.0pt;font-family:"Arial","sans-serif"; color:windowtext}tr.ea{height:17.5pt}td.eb{width:459.8pt;border:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:17.5pt}span.ec{font-size:10.0pt; font-family:"Arial","sans-serif";color:windowtext}tr.du{height:40.6pt}td.dx{width:252.35pt;border:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:40.6pt}span.dy{font-size:10.0pt;font-family: "Arial","sans-serif"}td.dv{width:204.7pt;border:solid black 1.0pt;border-left:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:40.6pt} p.ep{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;text-align: center}tr.ds{height:14.0pt}td.dt{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:14.0pt}tr.do{height:20.85pt}td.dr{width:411.2pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:20.85pt}td.dp{width:40.6pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:20.85pt}span.dq{font-size:10.0pt;font-family:"Segoe UI Symbol","sans-serif"}tr.dl{height:22.65pt}td.dn{width:411.2pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.65pt}td.dm{width:40.6pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:22.65pt} tr.di{height:19.5pt}td.dk{width:411.2pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:19.5pt}td.dj{width:40.6pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:19.5pt}td.dh{width:105.4pt;border-top:none;border-left:solid black 1.0pt; border-bottom:solid black 1.0pt;border-right:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:19.5pt}td.dg{width:297.8pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:19.5pt}td.df{border:none}tr.db{height:27.0pt}td.dd{width:249.4pt;border:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:27.0pt}span.de{font-size:10.0pt; font-family:"Arial","sans-serif"}td.dc{width:202.4pt;border:solid black 1.0pt;border-left:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:27.0pt} tr.cy{height:27.75pt}td.da{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:27.75pt}td.cz{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:27.75pt}tr.cv{height:25.1pt}td.cx{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:25.1pt}td.cw{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:25.1pt}tr.cs{height:22.1pt}td.cu{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.1pt}td.ct{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:22.1pt}tr.cp{height:27.5pt} td.cr{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:27.5pt}td.cq{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:27.5pt}tr.cn{height:12.15pt}td.co{width:465.1pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:12.15pt}tr.cl{height:15.4pt}td.cm{width:465.1pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:15.4pt}tr.ch{height:33.15pt}td.ck{width:83.45pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.cj{width:107.55pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.ci{width:258.1pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt} tr.ca{height:22.15pt}td.cf{width:50.85pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}span.cg{font-size: 10.0pt;font-family:"Arial","sans-serif"}td.ce{width:48.7pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.cd{width:48.7pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:22.15pt}td.cc{width:88.85pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.cb{width:104.55pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.bz{width:48.7pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:14.0pt}td.by{width:32.15pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:14.0pt}td.bx{width:48.2pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:14.0pt} td.bw{width:48.35pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:14.0pt}tr.bo{height:45.5pt}td.bu{width:83.45pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:45.5pt}span.bv{font-size:10.0pt;font-family:"Arial","sans-serif"; color:#333333;background:white}td.bt{width:50.85pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}td.bs{width:48.7pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}td.br{width:32.15pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}td.bq{width:48.2pt;border-top:none;border-left:none;border-bottom: solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}td.bp{width:48.35pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:45.5pt}tr.bm{height:19.0pt} td.bn{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:19.0pt}tr.bk{height:18.5pt}td.bl{width:459.8pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:18.5pt}tr.be{height:77.15pt}td.bj{width:102.75pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}td.bi{width:66.65pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}td.bh{width:76.4pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}td.bg{width:102.7pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}td.bf{width:79.3pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:77.15pt}tr.ay{height:41.9pt} td.bd{width:102.75pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:41.9pt}td.bc{width:66.65pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:41.9pt}td.bb{width:76.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:41.9pt}td.ba{width:102.7pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:41.9pt}td.az{width:79.3pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:41.9pt}tr.aw{height:24.15pt}td.ax{width:465.1pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:24.15pt}td.av{width:465.1pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:18.5pt}td.au{width:82.35pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.at{width:45.8pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:33.15pt} td.as{width:53.6pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:33.15pt}td.ar{width:64.9pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:33.15pt}td.aq{width:91.15pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.ap{width:87.3pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:33.15pt}td.ao{width:82.35pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.an{width:45.8pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.am{width:53.6pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.al{width:64.9pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.ak{width:91.15pt;border-top:none; border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt}td.ai{width:43.35pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:22.15pt} p.eq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;border:none;font-weight: bold; text-align: center}td.ah{width:35.8pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:22.15pt}tr.ae{height:17.1pt}td.ag{width:43.35pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:17.1pt}td.af{width:35.8pt;border-top:none;border-left: none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:17.1pt}tr.ac{height:18.4pt}td.ad{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:18.4pt}tr.z{height:11.15pt}td.ab{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:11.15pt}td.aa{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:11.15pt} td.y{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:19.0pt}td.x{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:19.0pt}tr.v{height:25.25pt}td.w{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:25.25pt}tr.t{height:99.45pt}td.u{width:459.8pt;border:solid black 1.0pt; border-top:none;padding:4.0pt 4.0pt 4.0pt 4.0pt;height:99.45pt}td.s{width:459.8pt;border:solid black 1.0pt; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:12.15pt}td.r{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:18.5pt}td.q{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:18.5pt}tr.n{height:36.5pt} td.p{width:249.4pt;border:solid black 1.0pt;border-top:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:36.5pt}td.o{width:202.4pt;border-top:none;border-left:none; border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:36.5pt}tr.k{height:39.5pt}td.m{width:249.4pt;border:solid black 1.0pt;padding:4.0pt 4.0pt 4.0pt 4.0pt; height:39.5pt}td.l{width:202.4pt;border:solid black 1.0pt;border-left:none; padding:4.0pt 4.0pt 4.0pt 4.0pt;height:39.5pt} /**/
RNS Number : 6675M
e-Therapeutics plc
17 September 2019
 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

E-Therapeutics plc

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

 

     

 

 

3. Full name of person(s) subject to the notification obligation: iii

Rupert Labrum

4. Full name of shareholder(s)

(if different from 3.): iv

 

5. Date of the transaction and date on which the threshold is crossed or reached: v

17/09/2019

6. Date on which issuer notified:

17/09/2019

7. Threshold(s) that is/are crossed or

reached: vi, vii

6.00%

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B2823H99


 

13449017

13449017

17162547

17162547

 

6.39%

 

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date xiii

Exercise/
Conversion
Period xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

 

 

 

 

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise
price

Expiration
date xvii

Exercise/
Conversion
period xviii

Number of voting
rights instrument
refers to

% of voting rights xix, xx

 

 

 

 

 

Nominal

Delta

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

17162547

6.39%

 

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

 

12. Date on which proxy holder will cease to hold voting rights:

 

 

 

13. Additional information:

 

14. Contact name:

 Rupert Labrum

15. Contact telephone number:

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
HOLEASNXFAPNEFF

Quick facts: e-Therapeutics plc

Price: 3.1745

Market: AIM
Market Cap: £8.54 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

2 weeks ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Holding(s) in Company

3 weeks, 4 days ago

Holding(s) in Company

3 weeks, 4 days ago

Half-year Report

on 10/07/2019